NCT07345390

Safety, Efficacy and Pharmacokinetic Characteristics of KR230109 Cream in Facial Acne Vulgaris

A Multicenter, Double-blind, Placebo-parallel-controlled Phase Ⅱ Clinical Trial to Evaluate the Safety, Efficacy and Pharmacokinetic Characteristics of KR230109 in Patients With Acne Vulgaris

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 180 (estimated)
• Sponsor: Jiangxi Kvvit Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 40 Years
• Healthy volunteers: Accepted

Summary

This study will evaluate the safety, efficacy and pharmacokinetics of KR230109 cream compared with placebo in Patients (18-40 Years) with Acne vulgaris

Conditions

• Acne Vulgaris

Interventions

Type	Name	Description
DRUG	KR230109 cream 0.025%	KR230109 cream 0.025% is indicated for the topical treatment of acne vulgaris in patients
DRUG	KR230109 cream 0.05%	KR230109 cream 0.05% is indicated for the topical treatment of acne vulgaris in patients
DRUG	Placebo	Vehicle cream manufactured to mimic look and feel of KR230109 Cream but without the active ingredient.

Timeline

• Start date: 2026-01-10
• Primary completion: 2026-10-30
• Completion: 2026-11-30
• First posted: 2026-01-15
• Last updated: 2026-01-15